Syneron Announces the Launch of elure(TM) Advanced Skin Whitening Technology in SingaporeBy Syneron Medical Ltd., PRNE
Sunday, November 7, 2010
YOKNEAM, Israel, November 8, 2010 - Today Syneron Medical Ltd. (Nasdaq: ELOS), www.syneron.com,
announces the initial commercial launch in Singapore of elure(TM) Advanced
Skin Whitening Technology, the first and only skin lightening product that
works by directly breaking down melanin - the molecule that accumulates in
the skin to cause a darkened appearance. This novel targeted mechanism of
action found only in elure provides the pathway for a meaningful improvement
in the skin's tone, texture and radiance in as little as seven days. More
than this, elure lightens the skin without the commonly reported side effects
of traditional skin lightening products, such as skin irritation. "elure is a
much anticipated breakthrough in skin lightening," said Vivian W. Bucay, MD,
US dermatologist and renowned skincare expert. "Now my patients and their
friends can experience very visible results in just a matter of days."
The organically-based active ingredient of elure was developed after
almost 30 years of research on a naturally occurring enzyme. "Lignin
peroxidase, the active ingredient of elure, is a natural enzyme derived from
a mushroom that grows on trees called Phanerochaete chrysosporium," said
Yoram Karmon, PhD, one of the pioneer researchers of elure that also included
Paula Belinky, MD, from Migal Galilee Technological Center in Kiryat Shmona,
and Carlos Dosoretz, PhD, from the Technion-Israel Institute of Technology in
Haifa. "Our research confirmed that lignin peroxidase uniquely breaks down or
depolymerizes melanin in human skin."
In clinical trials using elure, Alain Khaiat, PhD, President of the
Cosmetic Toiletries and Fragrance Association of Singapore and a 30-year
veteran in skincare product development, noted, "The safety and tolerability
of elure is unparalleled. We tested the product at 17,000 times the
recommended human dose and saw no potential for adverse events." Shimon
Eckhouse, MD, Chairman and co-founder of Syneron commented, "The first
commercial launch of elure in Asia marks an extremely important milestone for
Syneron, entering one of the largest world cosmetic markets with a unique,
patented product. This milestone emphasizes our strategy of serving all of
our customer needs in the areas of aesthetic medicine with safe and effective
In the Southeast Asian countries of Singapore, Malaysia and Indonesia,
elure will be marketed by Elure Singapore Pte. Ltd.
For more information about elure, visit www.elureskin.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. - a company devoted to real technology, real science
and real results - is the leading global aesthetic device company with a
comprehensive product portfolio and a global distribution footprint. The
Company's technology enables physicians to provide advanced solutions for a
broad range of medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and the
treatment of acne, leg veins and cellulite. The Company sells its products
under two distinct brands, Syneron and Candela. With its innovative approach
to aesthetic treatments, Syneron has now entered into one of the largest
in-demand applications, skin lightening. Founded in 2000, the corporate, R&D,
and manufacturing headquarters for Syneron Medical Ltd. are located in
Israel. Syneron also has R&D and manufacturing operations in the US. The
company markets and services and supports its products in 86 countries. It
has offices in North America, France, Germany, Italy, Portugal, Spain, UK,
Australia, China, Japan, and Hong Kong and distributors worldwide.
Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations,
beliefs, goals, plans or prospects constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Further, any statements that are not statements of historical fact (including
statements containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions) should also
be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements, including
the risk that the businesses of Syneron and Candela may not be integrated
successfully; the risk that the merger transaction with Candela may involve
unexpected costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to realize
than expected; the risk that disruptions from the merger transaction make it
more difficult to maintain relationships with customers, employees, or
suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most
recent Annual Report on Form 20-F, and the other factors described in the
filings that Syneron Medical Ltd. makes with the SEC from time to time. If
one or more of these factors materialize, or if any underlying assumptions
prove incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results, performance or
achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and
beliefs of Syneron Medical Ltd. as of the date of this document. Syneron
Medical Ltd. anticipates that subsequent events and developments will cause
its expectations and beliefs to change. However, while Syneron Medical Ltd.
may elect to update these forward-looking statements publicly in the future,
it specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential impact of any
future dispositions or strategic transactions that may be undertaken. These
forward-looking statements should not be relied upon as representing Syneron
Medical Ltd.'s views as of any date after the date of this document.
Contact: Tom Albright President and General Manager Topical Aesthetic Division, Syneron Medical Ltd. Office: +1-949-716-6670 (Extension 235) Cell: +1-949-632-9226 firstname.lastname@example.org Jane W. Smith Director of Marketing Communications Candela Corporation Office: +1-508-358-7637 (Extension 247) Cell: +1-978-314-1053 email@example.com
Tom Albright, President and General Manager, Topical Aesthetic Division, Syneron Medical Ltd., +1-949-716-6670 Extension 235, Cell: +1-949-632-9226, talbright at syneron.com, or Jane W. Smith, Director of Marketing Communications, Candela Corporation, +1-508-358-7637 Extension 247, Cell: +1-978-314-1053, jane.smith at candelalaser.com
Tags: Israel, November 8, Syneron Medical Ltd., Western Europe, Yokneam